South Korea · Delayed Price · Currency is KRW PharmaResearch Statistics
Total Valuation
PharmaResearch has a market cap or net worth of KRW 4.27 trillion. The enterprise value is 3.97 trillion.
| Market Cap | 4.27T |
| Enterprise Value | 3.97T |
Important Dates
The last earnings date was Tuesday, November 11, 2025.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
PharmaResearch has 10.39 million shares outstanding. The number of shares has decreased by -6.09% in one year.
| Current Share Class | 10.39M |
| Shares Outstanding | 10.39M |
| Shares Change (YoY) | -6.09% |
| Shares Change (QoQ) | +11.32% |
| Owned by Insiders (%) | 34.92% |
| Owned by Institutions (%) | 13.21% |
| Float | 5.58M |
Valuation Ratios
The trailing PE ratio is 28.22 and the forward PE ratio is 19.20. PharmaResearch's PEG ratio is 0.39.
| PE Ratio | 28.22 |
| Forward PE | 19.20 |
| PS Ratio | 8.61 |
| PB Ratio | 6.19 |
| P/TBV Ratio | 6.80 |
| P/FCF Ratio | 33.94 |
| P/OCF Ratio | 26.51 |
| PEG Ratio | 0.39 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.74, with an EV/FCF ratio of 31.56.
| EV / Earnings | 26.25 |
| EV / Sales | 8.01 |
| EV / EBITDA | 18.74 |
| EV / EBIT | 20.24 |
| EV / FCF | 31.56 |
Financial Position
The company has a current ratio of 7.57, with a Debt / Equity ratio of 0.31.
| Current Ratio | 7.57 |
| Quick Ratio | 6.55 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.00 |
| Debt / FCF | 1.68 |
| Interest Coverage | 16.41 |
Financial Efficiency
Return on equity (ROE) is 23.58% and return on invested capital (ROIC) is 16.62%.
| Return on Equity (ROE) | 23.58% |
| Return on Assets (ROA) | 15.05% |
| Return on Invested Capital (ROIC) | 16.62% |
| Return on Capital Employed (ROCE) | 21.87% |
| Revenue Per Employee | 1.10B |
| Profits Per Employee | 336.10M |
| Employee Count | 450 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.91 |
Taxes
In the past 12 months, PharmaResearch has paid 44.84 billion in taxes.
| Income Tax | 44.84B |
| Effective Tax Rate | 23.58% |
Stock Price Statistics
The stock price has increased by +87.24% in the last 52 weeks. The beta is 0.50, so PharmaResearch's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | +87.24% |
| 50-Day Moving Average | 510,480.00 |
| 200-Day Moving Average | 477,182.50 |
| Relative Strength Index (RSI) | 39.61 |
| Average Volume (20 Days) | 196,227 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaResearch had revenue of KRW 496.03 billion and earned 151.24 billion in profits. Earnings per share was 14,561.81.
| Revenue | 496.03B |
| Gross Profit | 377.44B |
| Operating Income | 196.18B |
| Pretax Income | 190.18B |
| Net Income | 151.24B |
| EBITDA | 211.90B |
| EBIT | 196.18B |
| Earnings Per Share (EPS) | 14,561.81 |
Balance Sheet
The company has 539.21 billion in cash and 211.33 billion in debt, giving a net cash position of 327.88 billion or 31,558.23 per share.
| Cash & Cash Equivalents | 539.21B |
| Total Debt | 211.33B |
| Net Cash | 327.88B |
| Net Cash Per Share | 31,558.23 |
| Equity (Book Value) | 689.45B |
| Book Value Per Share | 63,619.74 |
| Working Capital | 600.28B |
Cash Flow
In the last 12 months, operating cash flow was 161.09 billion and capital expenditures -35.30 billion, giving a free cash flow of 125.80 billion.
| Operating Cash Flow | 161.09B |
| Capital Expenditures | -35.30B |
| Free Cash Flow | 125.80B |
| FCF Per Share | 12,107.94 |
Margins
Gross margin is 76.09%, with operating and profit margins of 39.55% and 30.49%.
| Gross Margin | 76.09% |
| Operating Margin | 39.55% |
| Pretax Margin | 38.34% |
| Profit Margin | 30.49% |
| EBITDA Margin | 42.72% |
| EBIT Margin | 39.55% |
| FCF Margin | 25.36% |
Dividends & Yields
This stock pays an annual dividend of 1,100.00, which amounts to a dividend yield of 0.27%.
| Dividend Per Share | 1,100.00 |
| Dividend Yield | 0.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 5 |
| Payout Ratio | 7.94% |
| Buyback Yield | 6.09% |
| Shareholder Yield | 6.35% |
| Earnings Yield | 3.54% |
| FCF Yield | 2.95% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaResearch has an Altman Z-Score of 10.62 and a Piotroski F-Score of 7.
| Altman Z-Score | 10.62 |
| Piotroski F-Score | 7 |